Evidence map›Paper›PMID 32683952›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2020

Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.

Tae Hyo Kim, Bubu A Banini, Faizal Z Asumda, Nellie A Campbell, Chunling Hu, Catherine D Moser, Abdirashid M Shire, Shaoshan Han, Chenchao Ma, Anuradha Krishnan and 6 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. The Genetics behind Sulfation: Impact on Airway Remodeling.Journal of personalized medicine · 2024
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 2 countries.

Tae Hyo KimDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Bubu A BaniniDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.ORCID 0000-0002-2972-9263
Faizal Z AsumdaDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Nellie A CampbellDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Chunling HuDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Catherine D MoserDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Abdirashid M ShireDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Shaoshan HanDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Chenchao MaDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Anuradha KrishnanDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Taofic MounajjedDivision of Anatomic Pathology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Thomas A WhiteRobert & Arlene Kogod Center on Aging, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Gregory J GoresDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Nathan K LeBrasseurDivision of Anatomic Pathology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Michael R CharltonDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.
Lewis Rowland RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, and Mayo Clinic Cancer Center, Rochester, Minnesota.ORCID 0000-0001-7885-8574
Mayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI GREGORY J. GORES · 2009 to 2026
$22.2M
Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Rory Smoot · 2018 to 2026
$20.5M
Regulation of the Tumor Microenvironment in Hepatocellular CarcinomaR01CA165076 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO, ROBERTS, LEWIS R · 2012 to 2016
$2.0M
Molecular Pathogenesis of Hepatocellular CarcinomaR01CA100882 · NCI · MAYO CLINIC ROCHESTER · PI ROBERTS, LEWIS R · 2004 to 2008
$1.8M
Dysregulation of the Tumor Microenvironment in Hepatocellular CarcinomaR21CA128633 · NCI · MAYO CLINIC ROCHESTER · PI ROBERTS, LEWIS R · 2009 to 2010
$366k
Molecular Pathogenesis of Hepatocellular CarcinomaR56CA100882 · NCI · MAYO CLINIC ROCHESTER · PI ROBERTS, LEWIS R · 2009 to 2009
$352k
HHS | National Institutes of Health (NIH) CA100882HHS | National Institutes of Health (NIH) CA128633HHS | National Institutes of Health (NIH) CA165076HHS | National Institutes of Health (NIH) CA210964Mayo Clinic Cancer Center CA15083Mayo Clinic Center for Cell Signaling and GI DK084567NCATS NIH HHS UL1 TR001863NCI NIH HHS N01 CA015083NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA210964NCI NIH HHS R01 CA100882NCI NIH HHS R01 CA165076NCI NIH HHS R21 CA128633NCI NIH HHS R56 CA100882NIDDK NIH HHS P30 DK084567
6 · The paper itself

Abstract

Sulfatase 2 (SULF2) is a heparan sulfate editing enzyme that regulates the milieu of growth factors and cytokines involved in a variety of cellular processes. We used a murine model of diet-induced steatohepatitis to assess the effect of SULF2 downregulation on the development of nonalcoholic steatohepatitis (NASH) and liver fibrosis. Wild-type B6;129 mice (WT) and

Indexed as

AnimalsDiet, WesternDown-RegulationDyslipidemiasFast FoodsFatty LiverFemaleInsulin ResistanceLiver CirrhosisMaleMiceMice, 129 StrainMice, KnockoutNon-alcoholic Fatty Liver DiseaseRNA, Small InterferingSulfatasesRNA, Small InterferingSulf2 protein, mouseSulfatasesfast-food dietliver fibrosisnonalcoholic fatty liver diseasenonalcoholic steatohepatitisobesitySULF2sulfatase

Identifiers

PMID32683952
PMCPMC7509257
OpenAlexW3045384480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.